Introduction {#s1}
============

Tuberculosis (TB) is an important infectious disease plaguing the developed and developing countries worldwide, with more than nine million new cases of active tuberculosis reported annually. Isoniazid (INH), rifampicin (RIF) and pyrazinamide (PZA) are all widely used as first-line multidrug therapy for TB. Anti-tuberculosis drug induced liver injury (ATLI), a common serious adverse drug reaction, is one of the most challenging clinical problems, cause of hospitalization and life-threatening events. ATLI can be fatal if therapy is not interrupted on time, and the subsequent adherence problem may cause treatment failure and, relapse or drug resistance [@pone.0047769-Tostmann1], [@pone.0047769-Saukkonen1].

Of the various antituberculosis regimens, isoniazid is the main drug to induce hepatotoxicity [@pone.0047769-Lee1]. Metabolic intermediates of isoniazid are incriminated to be the cause of hepatotoxicity. In the liver, isoniazid is first metabolized into acetylisoniazid via N-acetyltransferase (NAT) [@pone.0047769-Mitchell1], followed by hydrolysis to acetylhydrazine. Acetylhydrazine is proposed to be oxidized into hepatotoxic intermediates by cytochrome P450 2E1 (CYP2E1) [@pone.0047769-RungeMorris1] and some hepatotoxic intermediates can be detoxified by glutathione S-transferase (GST) enzyme [@pone.0047769-Strange1]. Drug-metabolizing enzymes (DME) have critical effects on both the synthesis and detoxification of reactive metabolites [@pone.0047769-Naisbitt1]. Therefore, studies on genetic predisposition for anti-TB drug-induced liver injury have focused on a few metabolizing enzymes including N-acetyltransferase 2 (NAT2), CYP2E1, GSTM1 and GSTT1.

Over the past few years, considerable efforts have been devoted to exploring the relationships between the DME polymorphisms and ATLI among various populations. However, existing studies have yielded inconsistent results. These disparate findings may be due partly to insufficient power, false-positive results, and publication biases. Therefore, we performed a meta-analysis of the published studies to clarify this inconsistency and obtain summary risk estimates for the association of specific polymorphism in DME and risk of ATLI.

Materials and Methods {#s2}
=====================

Literature Search Strategy {#s2a}
--------------------------

Eligible literature published before the end of May 2012 were identified through a search of PubMed, EMBASE, ISI Web of Science and CNKI (Chinese National Knowledge Infrastructure) without language restriction. Search term combinations were as follows: drug-metabolising enzymes, antitubercular agents, drug-induced hepatotoxicity, drug-induced liver injury, genetic polymorphism, arylamine N-acetyltransferase, glutathione-S-transferase, cytochrome 2E1, acetylator phenotype, genetic susceptibility. All reference lists from the main reports and relevant reviews were hand searched for additional eligible studies.

Eligible Studies and Data Extraction {#s2b}
------------------------------------

Eligible studies had to meet all of the following criteria: (i) the studies were published in peer-reviewed journals and were independent studies using original data; (ii) the studies provided genotype distribution information of polymorphism in both cases and controls or odds ratio (OR) with its 95% confidence interval and P value; (iii) the studies investigated the DME polymorphism using either case-control or cohort design; (iv) the studies described the genotyping method, equipment, and protocols used or provided reference to them and (v) the studies used TB patients without ATLI as controls.

For each study, the following data were extracted independently by two authors: first author's surname, year of publication, diagnosis criterion, age, sex, ethnicity, genotyping method, total number of cases and controls and genotype frequency in cases and controls. The results were compared, and disagreements were discussed and resolved with consensus.

Statistical Methods {#s2c}
-------------------

The proposed risk genotypes are NAT2 slow acetylator (without wild-type NAT2\*4 allele), CYP2E1\*1A/\*1A (homozygous wild type c1/c1) and homozygous null GST genotype (GSTM1 null/null or GSTT1 null/null). Our primary analysis for measuring the overall effects of every DME was to compare the genotype distribution for ATLI patients against controls by the contrast of the above risk genotypes vs. other combined genotypes.

Odds ratio (OR) with 95% confidence intervals (CIs) was used to assess the strength of association between gene polymorphism and ATLI risk. Cochran's chi-square-based Q statistic test was performed in order to assess possible heterogeneity between the individual studies and thus to ensure that each group of studies was suitable for meta-analysis. ORs were pooled according to the method of DerSimonian and Laird that takes into account the variation between studies, and 95% CI were constructed using Woolf's method [@pone.0047769-DerSimonian1], [@pone.0047769-Woolf1]. The Z test was used to determine the significance of the pooled OR. Sensitivity analyses were performed to assess the stability of the results, namely, a single study in the meta-analysis was deleted each time to reflect the influence of the individual data set to the overall OR. Publication bias was assessed using Egger's test [@pone.0047769-Egger1] and Begg's funnel plots [@pone.0047769-Begg1]. All P values are two-sided, and P\<0.05 were considered statistically significant. Statistical analyses were done with Stata (version 10.0).

Results {#s3}
=======

Characteristics of Studies {#s3a}
--------------------------

The combined search yielded 412 references. Study selection process was shown in [Figure S1](#pone.0047769.s001){ref-type="supplementary-material"}. A total of 38 studies were finally included with 2,225 patients and 4,906 controls [@pone.0047769-Tang1]--[@pone.0047769-Vuilleumier1]. For the CYP2E1, 13 studies were available, including a total of 674 cases and 1,990 controls. For the NAT2, 24 studies involved a total of 1,116 cases and 2,655 controls. For the GST M1, 11 studies involved a total of 896 cases and 1,604 controls. For the GST T1, 10 studies involved a total of 792 cases and 1,493 controls. Of the cases, 80% were East Asian, 8% were Indian, 7% were Caucasian, and 5% were of other ethnic populations. The detailed characteristics of the studies included in this meta-analysis are shown in [Table 1](#pone-0047769-t001){ref-type="table"}.
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###### Characteristics of the studies included in the meta-analysis.

![](pone.0047769.t001){#pone-0047769-t001-1}

  Study                                        Year   Ethnicity              Gene              No. of case/control   Mean age of case/control   Gender component in caseand control (% male)   Genotyping method
  ------------------------------------------- ------ ----------- ---------------------------- --------------------- -------------------------- ---------------------------------------------- -------------------
  Tang [@pone.0047769-Tang1]                   2012    Chinese       CYP2E1; GSTM1; GSTT1            89/356                 32.7/43.6                            73.0/73.0                           RFLP
  An [@pone.0047769-An1]                       2012    Chinese          NAT 2; CYP2E1                101/107                36.0/33.4                            55.4/70.0                        Sequencing
  Rana [@pone.0047769-Rana1]                   2012    Indian                NAT2                    50/201                 45.3/43.8                            24.8/75.2                           RFLP
  Mahmoud [@pone.0047769-BenMahmoud1]          2011   Tunisian               NAT2                     14/52                 42.4/42.1                            42.8/48.1                           RFLP
  Zhu [@pone.0047769-Zhu1]                     2011    Chinese           GSTM1; GSTT1                228/300                39.8/37.5                            57.9/53.3                            PCR
  Fernandez [@pone.0047769-LeiroFernandez1]    2011    Spanish               NAT2                     50/67                  34/30.5                             54.0/56.7                           RFLP
  Sotsuka [@pone.0047769-Sotsuka1]             2011   Japanese    NAT2; CYP2E1; GSTM1; GSTT1          52/92                 54.9/50.4                            92.3/73.9                         RFLP; PCR
  Sistanizad [@pone.0047769-Sistanizad1]       2011    Iranian               NAT2                     14/36                 43.1/49.6                            57.1/55.5                           RFLP
  Huang [@pone.0047769-Huang1]                 2011    Chinese               NAT2                    119/198                41.0/44.0                            66.4/64.1                        Sequencing
  Teixeira [@pone.0047769-Teixeira1]           2011   Brazilian      CYP2E1; GSTM1; GSTT1            26/141                 47.6/43.0                            61.5/52.5                      Sequencing; PCR
  Yimer [@pone.0047769-Yimer1]                 2011   European               NAT2                    41/160                   NA/NA                                NA/NA                          Sequencing
  Bose [@pone.0047769-Bose1]                   2011    Indian            NAT2; CYP2E1                41/177                 38.0/36.0                            43.9/47.4                           RFLP
  Chatterjee [@pone.0047769-Chatterjee1]       2010    Indian            GSTM1; GSTT1                51/100                 37.2/33.2                            49.0/63.0                            PCR
  Wang [@pone.0047769-Wang1]                   2010    Chinese          GSTM1; CYP2E1                104/111                48.6/44.7                            67.3/67.6                            PCR
  Lee [@pone.0047769-Lee2]                     2010    Chinese           NAT2; CYP2E1                 45/95                 58.4/54.9                            60.0/66.3                          Taqman
  Kim [@pone.0047769-Kim1]                     2010    Korean            GSTM1; GSTT1                57/190                 47.3/42.4                            59.6/67.9                            PCR
  Wu [@pone.0047769-Wu1]                       2010    Chinese               NAT2                    155/162                  NA/NA                              58.0/60.0                          Taqman
  Guo [@pone.0047769-Guo1]                     2010    Chinese               NAT2                    106/106                48.8/48.6                            68.9/68.9                           RFLP
  Chen [@pone.0047769-Chen1]                   2010    Chinese              CYP2E1                   103/236                45.0/45.7                            78.6/66.1                           RFLP
  Wang [@pone.0047769-Wang2]                   2009    Chinese              CYP2E1                   104/111                47.7/45.5                            61.1/64.0                           RFLP
  Guo [@pone.0047769-Guo2]                     2009    Chinese           GSTM1; GSTT1                106/106                48.8/48.6                            68.9/68.9                            PCR
  Kim [@pone.0047769-Kim2]                     2009    Korean                NAT2                    67/159                 42.1/42.8                            65.7/65.4                         SNPstream
  Yamada [@pone.0047769-Yamada1]               2009   Japanese           NAT2; CYP2E1                23/147                   NA/NA                              13.0/42.8                     Sequencing, RFLP
  Wang [@pone.0047769-Wang3]                   2009    Chinese               NAT2                     36/36                   NA/NA                                NA/NA                             RFLP
  Leiro [@pone.0047769-Leiro1]                 2008    Spanish           GSTM1; GSTT1                 35/60                 34.0/31.0                            40.0/41.7                            PCR
  Bozok [@pone.0047769-BozokCetintas1]         2008    Turkish               NAT2                     30/70                 39.8/37.3                            50.0/72.8                            PCR
  Possuelo [@pone.0047769-Possuelo1]           2008   Brazilian              NAT2                    14/240                 38.9/36.5                            50.0/67.9                        Sequencing
  Huang [@pone.0047769-Huang2]                 2007    Chinese           GSTM1; GSTT1                115/115                60.3/59.1                            63.5/63.5                            PCR
  Cho [@pone.0047769-Cho1]                     2007    Korean            NAT2; CYP2E1                18/114                 51.2/46.7                            66.7/55.3                        Sequencing
  Higuchi [@pone.0047769-Higuchi1]             2007   Japanese               NAT2                     18/82                 60.8/64.7                            50.0/57.3                           RFLP
  Vuilleumier [@pone.0047769-Vuilleumier1]     2006     Swiss               CYP2E1                    34/55                   NA/NA                                NA/NA                             RFLP
  Shimizu [@pone.0047769-Shimizu1]             2006   Japanese               NAT2                     10/32                 60.5/64.9                            70.0/46.9                           RFLP
  Roy [@pone.0047769-Roy1]                     2006    Indian               CYP2E1                    8/101                   NA/NA                                NA/NA                             RFLP
  Wang [@pone.0047769-Wang4]                   2004    Chinese               NAT2                     32/35                   NA/NA                              53.1/45.7                           RFLP
  Huang [@pone.0047769-Huang3]                 2003    Chinese           NAT2; CYP2E1                49/269                 70.0/59.0                            18.4/14.9                           RFLP
  Huang [@pone.0047769-Huang4]                 2002    Chinese               NAT2                    33/191                 73.3/63.7                            87.9/88.5                           RFLP
  Roy [@pone.0047769-Roy2]                     2001    Indian         NAT2; GSTM1; GSTT1              33/33                   NA/NA                                NA/NA                              PCR
  Ohno [@pone.0047769-Ohno1]                   2000   Japanese               NAT2                     14/63                   NA/NA                                NA/NA                             RFLP

Association of CYP2E1 Gene with ATLI {#s3b}
------------------------------------

Meta-analysis revealed no statistically significant association between ATLI and CYP2E1 c1/c1 genotype \[OR = 1.28; 95% CI: 0.97--1.69; *P(Z) = *0.08; *P(Q)* = 0.11\]. When studies were stratified for ethnicity, significant risks were found among East Asians \[OR = 1.35; 95% CI: 1.01--1.81; *P(Z)* = 0.04; *P(Q)* = 0.08\]. However, no significant associations were detected among Indian, Caucasian and other ethnic populations ([Figure 1](#pone-0047769-g001){ref-type="fig"}). In the subgroup analyses by sample size, the summary OR for big studies of the c1/c1 genotype was 1.36 \[95% CI: 0.92--2.00; *P(Z) = *0.12; *P(Q)* = 0.05\] and for small studies was 1.17 \[95% CI: 0.75--1.81; *P(Z) = *0.49; *P(Q)* = 0.28\].

![Forest plot from the meta-analysis of ATLI and *CYP2E1*.](pone.0047769.g001){#pone-0047769-g001}

Association of NAT2 Gene with ATLI {#s3c}
----------------------------------

Overall, there was evidence of an association between the increased risk of ATLI and the variant when all eligible studies were pooled into the meta-analysis. Using random effect model, the summary OR of the NAT2 slow acetylator genotype for ATLI was 3.18 \[95% CI: 2.49--4.07; *P(Z)* \<10^−5^; *P(Q)* = 0.03\]. When stratifying for ethnicity, an OR of 3.32 \[95% CI: 2.43--4.53; *P(Z)* \<10^−5^; *P(Q)* = 0.06\], 2.96 \[95% CI: 1.83--4.76; *P(Z)* \<10^−4^; *P(Q)* = 0.49\], 6.64 \[95% CI: 3.01--14.66; *P(Z)* \<10^−4^; *P(Q)* = 0.36\] and 5.24 \[95% CI: 2.18--12.60; *P(Z)* \<10^−4^; *P(Q)* = 0.93\] resulted for the slow acetylator genotype, among East Asian, Indian, Middle Eastern and other ethnic population, respectively ([Figure 2](#pone-0047769-g002){ref-type="fig"}). Unfortunately, we failed to detect any association to ATLI risk for Caucasians. Subsidiary analyses of control source yielded an overall OR for big studies of 2.48 \[95% CI: 1.87--3.30; *P(Z)* \<10^−5^; *P(Q)* = 0.26\] and for small studies of 3.92 \[95% CI: 2.75--5.58; *P(Z)* \<10^−5^; *P(Q)* = 0.06\].

![Forest plot from the meta-analysis of ATLI and *NAT2*.](pone.0047769.g002){#pone-0047769-g002}

Association of GSTM1 and GSTT1 Gene with ATLI {#s3d}
---------------------------------------------

For ATLI risk and the null genotype of GSTM1, our meta-analysis gave an overall OR of 1.43 \[95% CI: 1.08--1.88; *P(Z) = *0.01; *P(Q) = *0.02\] with statistically significant between-study heterogeneity. This analysis is based on pooling of data from a number of different ethnic populations. When stratifying for ethnicity, an OR of 1.55 \[95% CI: 1.12--2.13; *P(Z)* = 0.008; *P(Q)* = 0.02\] resulted for null genotype among East Asians; while no significant association was found among Caucasian and Indian populations ([Figure 3](#pone-0047769-g003){ref-type="fig"}). By considering sample size subgroups, the OR was 1.61 \[95% CI: 1.18--2.19; *P(Z) = *0.003; *P(Q)* = 0.005\] in big studies, compared to 1.26 \[95% CI: 0.54--2.95; *P(Z) = *0.59; *P(Q)* = 0.08\] in small studies.

![Forest plot from the meta-analysis of ATLI and *GST M1*.](pone.0047769.g003){#pone-0047769-g003}

The meta-analysis resulted in a statistically non-significant association between GSTT1 deficiency and ATLI. The overall OR was 1.07 \[95% CI: 0.82--1.39; *P(Z) = *0.61; *P(Q)* = 0.16\]. When stratifying for ethnicity, an OR of 0.96 \[95% CI: 0.78--1.18; *P(Z) = *0.69; *P(Q)* = 0.40\] and 2.92 \[95% CI: 0.79--10.89; *P(Z)* = 0.11; *P(Q)* = 0.45\] resulted for null genotype, among East Asian and Indian populations, respectively ([Figure 4](#pone-0047769-g004){ref-type="fig"}). No significant association was found in stratified analyses according to sample size. The OR was 0.97 \[95% CI: 0.79--1.19; *P(Z) = *0.76; *P(Q)* = 0.44\] in big studies, 1.88 \[95% CI: 0.68--5.20; *P(Z)* = 0.23; *P(Q)* = 0.15\] in small studies.

![Forest plot from the meta-analysis of ATLI and *GST T1*.](pone.0047769.g004){#pone-0047769-g004}

The effect of each genotype of GSTs was independently assessed. The data on both null genotype of GSTs among cases and controls were available in five studies, which included 460 cases and 1006 controls. The interaction between GSTM1 null and GSTT1 null, for which an OR of 1.12 \[95% CI: 0.86--1.48; *P(Z) = *0.40; *P(Q)* = 0.69\] for ATLI appeared in compared with individuals with the positive genotypes.

Sensitivity Analyses and Publication Bias {#s3e}
-----------------------------------------

Sensitivity analyses were performed to assess the influence of each individual study on the pooled OR by sequential removal of individual studies. The results suggested that no individual study significantly affected the pooled OR, thus suggesting that the results of this meta-analysis are stable.

A funnel plot of these 24 included studies concerning NAT2 and ATLI suggested a possibility of the preferential publication of positive findings in smaller studies (t = 3.72, *P* = 0.001; [Figure S2](#pone.0047769.s002){ref-type="supplementary-material"}). The shape of the funnel plots was symmetrical ([Figures S3](#pone.0047769.s003){ref-type="supplementary-material"}, [S4](#pone.0047769.s004){ref-type="supplementary-material"} and [S5](#pone.0047769.s005){ref-type="supplementary-material"}) for CYP2E1, GSTM1 and GSTT1. The statistical results still did not show publication bias in these studies for CYP2E1 (t = −1.27, *P* = 0.23), GSTM1 (t = 0.32, *P* = 0.76) and GSTT1 polymorphism (t = 1.65, *P* = 0.14).

Discussion {#s4}
==========

This is the most comprehensive meta-analysis concerning the relationship between polymorphisms of three DME genes and ATLI risk. Its strength was based on the accumulation of published data giving greater information to detect significant differences. In total, the meta-analysis involved 38 studies for ATLI that provided 2,225 patients and 4,906 controls. Our results demonstrated that the slow NAT2 genotype and GSTT1 null polymorphism is a risk factor for developing ATLI. Although no significant association between CYP2E1 \*1A polymorphism and ATLI susceptibility was detected in the overall comparison, we found that the CYP2E1 \*1A polymorphism was associated with increased risk of ATLI among East Asian populations when stratified by ethnicity. Ethnic differences may contribute to these different results, since the CYP2E1 c2 allele distribution of the polymorphism varies between East Asian and other ethnic populations [@pone.0047769-Tang2]. However, we failed to detect any positive relationship between ATLI and GSTT1 null polymorphism.

As the pathogenic mechanism of ATLI is poorly understood, most studies were based on INH metabolic pathway. For predicting ATLI, the NAT2 genotype is seemingly more important than other genotypes, because this genotype possesses high susceptibility to ATLI with OR of 3.18 compared with CYP2E1 (OR = 1.28) and GSTM1 (OR = 1.43). Slow acetylators not only acetylate isoniazid more slowly but also monoacetylhydrazine, the immediate precursor of the toxic intermediates, to the harmless diacetylhydrazine [@pone.0047769-Lauterburg1]. This protective acetylation is further suppressed by isoniazid. Therefore, slow acetylators may critically increase the accumulation of toxic metabolites indirectly. The action of NAT in the disposition of isoniazid is followed by CYP2E1. Earlier reports demonstrated CYP2E1 activity was less inhibited by isoniazid in subjects with CYP2E1 \*1A/\*1A genotype than in those with other genotypes [@pone.0047769-Huang3]. Therefore, under the administration of isoniazid, subjects with CYP2E1 \*1A/\*1A genotype have higher CYP2E1 activity than those with other genotypes, and, hence, may produce more hepatotoxins and finally increase the risk of liver injury.

GST, as an important phase II detoxification enzyme, was correlated to the susceptibility of alcoholic liver disease and many cancers [@pone.0047769-Strange1]. Subjects with homozygous 'null' mutant genotype of GSTM1 or GSTT1 have been found to lose enzymatic activity [@pone.0047769-Strange1]. It is speculated that people with null GSTM1 or GSTT1 genotypes could not detoxify the toxic reactive metabolites efficiently, and thus have higher risk of drug-induced liver injury and many cancers. However, failing to identify the association between GSTT1 polymorphism and ATLI may be due partly to the small sample size and low frequency of patients with ATLI; additional studies with large sample size are therefore needed to confirm our finds.

In interpreting the results, some limitations of this meta-analysis should be addressed. Firstly, lack of clarification regarding the exact criteria used for the diagnosis of ATLI, and the Hardy-Weinberg equilibrium status among controls in several studies may over inflate our results. Secondly, variation in the anti-TB drugs administered in the studies we analyzed limited the possibility of examining the association of DME with any specific drug. In these studies, multiple anti-TB drugs were utilized in some research, while some other adopts the single-drug therapy. Thirdly, our meta-analysis is based on unadjusted estimates, whereas a more precise analysis could be performed if individual data were available, which would allow for an adjustment estimate (by age, sex, alcohol consumption, cigarette smoking and other lifestyle). Additionally, it should be noted that the studies included patients from several different ethnic groups, with an overrepresentation of East Asian patients (e.g., Chinese, Korean, and Japanese populations) and an underrepresentation of individuals of Caucasian descent. Since allele frequencies may vary considerably between ethnic groups, careful consideration of the potential effect of population genetics on genotypic and phenotypic distribution is warranted, but the limited samples currently available have hampered this effort.

As a result of the heterogeneity of medication used, the duration of illness in different samples, and the different racial groups, it is possible that we have underestimated the effect size of the gene-drug response association. Furthermore, none of the studies formally accounted for medication noncompliance, which is prevalent in patients with TB. Put simply, when a patient does not take the prescribed anti-TB drug, the measured effect size of gene-drug response association is assessed as zero, whereas the true effect of genotype on the phenotype is perhaps larger. Nevertheless, despite the potential underestimation of effect size produced by these uncontrolled factors, we were still able to detect a significant association between the NAT2, GSTM1 and CYP2E1 polymorphism and anti-TB drug response. It is suggested that patients with high-risk genotypes should have regular liver biochemical tests in the first few months following administration of anti-TB drugs. Tailoring the anti-TB regimen to patients according to individual genetic profiles is expected in the coming years.

In summary, our meta-analysis indicates that CYP2E1, NAT2 and GSTM1 genetic variation is significantly associated with anti-tuberculosis drug-induced liver injury. Polymorphisms in these DME, such as NAT2\*4, may be particularly important in predicting clinical response to anti-TB drug treatment. Furthermore, interaction between candidate genes and other risk factors, such as diet, alcohol consumption, smoking, existing liver disease and other comorbid diseases, should be explored to realize the modification effect of these extrinsic factors to the expression of different genotypes.
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